V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Dyne Therapeutics Executive Compensation (FY25)

DYN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
John Cox
Median of the other named officers
$1,057,598
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 5, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Dyne Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 11, 2026Latest filing (8-K): June 8, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Dyne Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
221 figures on this page: 219 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

More on Dyne Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Cox: $20,688,724 → $2,076,868 (90.0% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Dyne Therapeutics' chief executive and what were they paid?
Total compensation for John Cox, President and Chief Executive Officer, came to $2,076,868 in fiscal 2025. Cox's total moved 90.0% lower from the $20,688,724 reported for fiscal 2024.
What was Dyne Therapeutics' say-on-pay result?
The say-on-pay proposal drew 99.1% support at the meeting held June 5, 2026 for fiscal 2025.
Which companies are in Dyne Therapeutics' peer group?
The disclosed peer group includes Arcellx, Arvinas, Beam Therapeutics, BridgeBio Pharma and Celldex Therapeutics, among others.
What is Dyne Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 6:1 for fiscal 2025, against median employee compensation of $338,650.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joshua Brumm
President and Chief Executive Officer
◇—◇◇◇—◇◇
Susanna High
Chief Operating Officer
◇—◇◇◇—◇◇
Oxana Beskrovnaya
Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Josh Brumm
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Jonathan McNeill
Chief Business Officer
◇—◇◇◇—◇◇
Susanna High
Chief Operating Officer
◇—◇◇◇—◇◇
Oxana Beskrovnaya
Chief Innovation Officer; Former Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Cox
President and Chief Executive Officer
◇—◇◇◇—◇◇
Josh Brumm
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Johanna Friedl-Naderer
Chief Commercial Officer
◇—◇◇◇——◇
Douglas Kerr
Chief Medical Officer
◇—◇◇◇—◇◇
Oxana Beskrovnaya
Chief Innovation Officer; Former Chief Scientific Officer
◇—◇◇◇—◇◇
Richard Scalzo
Former Senior Vice President, Head of Finance and Administration
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Erick Lucera
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
John Cox
President and Chief Executive Officer
◇——◇◇—◇◇
Johanna Friedl-Naderer
Chief Commercial Officer
◇——◇◇——◇
Douglas Kerr
Chief Medical Officer
◇——◇◇—◇◇
Oxana Beskrovnaya
Chief Innovation Officer; Former Chief Scientific Officer
◇——◇◇—◇◇
Richard Scalzo
Former Senior Vice President, Head of Finance and Administration
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Douglas KerrOPTION◇——◇—◇◇
Erick LuceraRSU◇——◇——◇
Erick LuceraOPTION◇——◇—◇◇
Johanna Friedl-NadererOPTION◇——◇—◇◇
John G. CoxOPTION◇——◇—◇◇
Oxana BeskrovnayaOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
John CoxOption◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Oxana BeskrovnayaRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Erick LuceraOption◇—◇—
Douglas KerrOption◇—◇—
Johanna Friedl-NadererOption◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Douglas Kerr
Chief Medical Officer · Offer letter · citing a 2024 filing
Non-compete period◇
Non-solicit period◇
Johanna Friedl-Naderer
Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
John Cox
President and Chief Executive Officer · Offer letter · citing a 2024 filing
Non-compete period◇
Non-solicit period◇
Oxana Beskrovnaya
Chief Innovation Officer; Former Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Richard Scalzo
Former Senior Vice President, Head of Finance and Administration · Consulting agreement
Change-in-control trigger◇
Equity acceleration on change in control◇
Excise tax treatment◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vikram Karnani
——◇———◇
Brian S. Posner
◇—◇———◇
Jason Rhodes
Board chair
◇—◇———◇
David Lubner
◇—◇———◇
Dirk Kersten
◇—◇———◇
Catherine Stehman-Breen, M.D
◇—◇———◇
Carlo Incerti, M.D
◇—◇———◇
Edward Hurwitz
◇—◇———◇
John G. Cox served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Arcellx ACLX
  • Arvinas ARVN
  • Beam Therapeutics BEAM
  • BridgeBio Pharma BBIO
  • Celldex Therapeutics CLDX
  • Crinetics Pharmaceuticals CRNX
  • CRISPR Therapeutics AG CRSP
  • Cytokinetics CYTK
  • Denali Therapeutics DNLI
  • IDEAYA Biosciences IDYA
  • Immunovant IMVT
  • Intellia Therapeutics NTLA
  • Keros Therapeutics KROS
  • Kymera Therapeutics KYMR
  • Nuvalent NUVL
  • Revolution Medicines RVMD
  • Rocket Pharmaceuticals RCKT
  • Xenon Pharmaceuticals XENE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 5, 2026=◇◇◇
2024May 30, 2025=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- John Cox (President and Chief Executive Officer), FY2025 total compensation $2,076,868 (base salary $721,000) [exec_comp, SEC accession 0001193125-26-173655, filed 2026-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Dyne Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Dyne Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Dyne Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Dyne Therapeutics' disclosed peer group is defensible, who names Dyne Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
221 figures on this page: 219 cited to the filing that reported them, 2 calculated from figures it prints.
219 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001193125-26-261696
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-173655
    CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards · and 3 more sections
  3. 0000950170-25-082317
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-066386
    Employment Agreement
  5. 0000950170-25-053950
    Summary Compensation Table
  6. 0000950170-24-042276
    Summary Compensation Table
  7. 0000950170-23-012196
    Summary Compensation Table
  8. 0000950170-24-124572
    EX-10.20
  9. 0001193125-24-075932
    EX-10.16
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Dyne Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/DYN (accessed 2026).
Short form: data: Velarion

The paid brief for Dyne Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Dyne Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Dyne Therapeutics discloses

The companies named in DYN's own disclosed peer group.

ArcellxArvinasBeam TherapeuticsBridgeBio PharmaCelldex TherapeuticsCrinetics PharmaceuticalsCRISPR Therapeutics AGCytokineticsDenali TherapeuticsIDEAYA BiosciencesImmunovantIntellia TherapeuticsKeros TherapeuticsKymera TherapeuticsNuvalentRevolution MedicinesRocket PharmaceuticalsXenon Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy